QuartzBio announced a strategic growth investment and the acquisition of a controlling interest from Eir Partners to accelerate the development of its AI-powered clinical trial intelligence platform for biopharma organizations. Financial terms of the transaction were not disclosed.
The company said the investment marks a significant milestone as it expands its role as operational infrastructure for clinical-stage biopharma companies seeking greater efficiency, operational control, and data integrity across clinical trial portfolios.
QuartzBio was developed to address operational inefficiencies in clinical development caused by fragmented biospecimen and biomarker data spread across vendors, systems, and spreadsheets. According to the company, these disconnected workflows can lead to unusable samples, missing data, consent-tracking issues, excessive manual oversight, and costly delays in clinical trials.
The company’s vendor-agnostic platform uses AI-enabled workflows to unify sample collection, chain-of-custody tracking, consent management, metadata integrity, and biomarker results into a centralized system that provides real-time operational visibility across clinical portfolios.
QuartzBio said its customer base includes multiple top 10 pharmaceutical companies. The platform is designed to identify and resolve operational issues early before they lead to protocol deviations, data loss, or delays. According to the company, customers have reported near-complete visibility into sample collection processes, monitoring effort reductions of up to 98%, and average savings ranging from $250,000 to $350,000 per Phase II and III clinical study.
The investment from Eir Partners will support additional product development initiatives including expanded interoperability across CROs, laboratories, and clinical systems; deeper AI-driven workflow automation; enhanced analytics and benchmarking tools; increased enterprise scalability and compliance capabilities; and expanded customer support infrastructure.
Support: Bourne Partners served as exclusive financial advisor to QuartzBio on the transaction.
KEY QUOTES:
“Modern clinical development generates unprecedented volumes of data, yet trial risk persists because that data is fragmented, delayed, or unreliable. This investment allows us to double down on delivering a scalable software platform that removes manual oversight, protects scientific integrity, and materially reduces trial cost and duration.”
Scott Marshall, Ph.D., CEO, QuartzBio
“AI is fundamentally transforming clinical development, and sample and biomarker intelligence represents one of its highest-impact applications. QuartzBio has demonstrated both strong product-market fit and tangible economic impact for sponsors managing complex portfolios. By embedding domain-specific AI directly into clinical and translational workflows, the company is well positioned to shape how next-generation trials are conducted.”
Brett Carlson, Founder And Chief Executive Officer, Eir Partners
